The Opening Bell
Ed Clay’s path to becoming one of the most forward-thinking innovators in modern medicine began long before he ever stepped into a hospital. Growing up in Nashville, he started boxing at thirteen, following in the footsteps of his father and uncle, who were both fighters. By twenty, his life had taken a sharp turn in a moment that could have ended his story rather than redirected it. Instead, Clay rebuilt his life with relentless discipline, eventually creating one of the largest MMA gyms in the country, coaching professional fighters, and launching an apparel brand that became the world’s largest manufacturer of Brazilian Jiu-Jitsu uniforms.
His trajectory shifted again in 2008 when he tore his LCL, PCL, and meniscus. Team doctors prescribed heavy opiate pain medications—common during an era of widespread overprescribing—and Clay developed a powerful accidental addiction. After two years, he attempted to stop but was overwhelmed by withdrawal. Six months into struggling on his own, he sought help from a therapist who recommended Ibogaine, explaining that it could interrupt withdrawal patterns. Clay traveled to Mexico for treatment and returned home seventy-two hours later without cravings and without withdrawal symptoms.
The turning point in Ed Clay’s life had nothing to do with business strategy or ambition. Instead, it was rooted entirely in his mother’s suffering. Her rheumatoid arthritis had progressed to the point that she had exhausted every conventional treatment available in the United States. Once vibrant and strong, she had deteriorated so severely that she could barely walk, and specialists had run out of options. Watching her decline left Clay devastated and determined to find something that could help her.
His search led him into the history of immunotherapy, where he discovered a 1923 study on the use of Coley’s toxins for rheumatoid arthritis. That discovery sent him down a deep investigative path that ultimately revealed a single hospital in Tijuana, Mexico, that had once used these treatments for autoimmune diseases and cancer. By the time he learned of it, the hospital had already closed.
Most people would have stopped there, but Clay didn’t. He tracked down the previous owner, and together with partners Scott Nelson and Deddrick Perry, negotiated to purchase the hospital. They rehired the original medical team, the very people who had delivered the therapies in the past, and brought his mother there as their first patient.
She arrived in a wheelchair. Three weeks later, she walked out on her own.
That moment reshaped Clay’s entire mission. From then on, he became committed to exploring every medical possibility available—constantly seeking stronger science, better collaboration, and more advanced treatments. It became the foundation for the medical ecosystem he would eventually build.
Why He Built Medical Ecosystems Instead of Clinics
To understand Clay’s model, one has to understand his core principle: logic. In his view, much of what is broken in modern healthcare stems from outdated habits—systems that persist simply because “that’s how it’s always been done.” When reexamined through the lens of what actually produces the best patient outcomes, the answers become unexpectedly clear.
This is why the Cellular Performance Institute and the TAM Center were designed as vertically integrated ecosystems. Every essential function, including cellular manufacturing, clinical laboratories, genomics, proteomics, digital pathology, and more, exists under one roof. Physicians and PhD-level scientists work side by side, collaborating in real time with full access to patient data and biospecimens. This structure eliminates delays, reduces costs, and enhances precision in ways that fragmented systems cannot match.
Their Chief Scientific Officer, Dr. Francesco Marincola—one of the world’s most published cancer immunologists and the former Chief of Infectious Disease and Immunogenetics at the NIH—introduced Clay to the true meaning of translational medicine: moving discoveries directly from the scientist’s bench to the patient’s bedside. Once Clay understood the framework, he committed to building the world’s best facility to support it.
Today, the TAM Center includes advanced cellular manufacturing suites, genomics and proteomics platforms, CT and MRI imaging, AI-powered diagnostics, interventional suites, an ICU, and a deeply aligned medical and scientific team. Beyond Mexico, the organization also operates a lab in Boston and is building a new Nashville lab designed to mirror its full capabilities, with a compounding pharmacy already complete.
What’s Broken in Traditional Healthcare and How Ed Clay is Fixing It
Traditional healthcare, Clay observes, is fundamentally reactive. It waits for disease to emerge, then attempts to address it within a fragmented structure—outsourced labs, disconnected departments, outdated protocols, and treatments that lack personalization. Meanwhile, the biotech industry has become slow and bloated, spending billions over many years to bring a single therapy forward, while patients continue to suffer.
At CPI and the TAM Center, that model has been reversed. Clay approaches cancer and complex disease as an engineering challenge, one defined by data design systems and optimization. They manufacture their own cell therapies, maintaining control over quality and cost. Their in-house genomics and proteomics platforms allow them to decode each patient’s biology with a depth matched by few institutions worldwide. AI-powered diagnostics guide more precise intervention, from imaging to digital pathology.
Most importantly, all departments function under one roof. Scientists, clinicians, lab teams, and manufacturers collaborate in real time rather than operating in silos. This is what translational medicine was meant to be: science moving quickly, logically, and in direct response to real patient data.
How Ed Clay Built a World-Class Scientific Team
Clay’s ability to attract extraordinary talent begins with vision. Transforming an entire medical system—especially one as entrenched and flawed as the current approach to cancer—requires individuals who not only possess exceptional expertise but also believe meaningful change is possible.
This shared purpose drew figures such as Dr. Francesco Marincola, one of the most published melanoma researchers in the world, and Dr. Ali Asadi, the former Chief of Innovation at Illumina, who helped develop the first FDA-approved pan-cancer 500-gene panel and engineered the chemistry behind a 10,000-protein platform. Additional experts such as Eric Hett and Vijay Mahant joined for the same reason.
These scientists could have worked anywhere: major academic institutions, billion-dollar biotechs, or top pharmaceutical companies. They chose TAM and CPI because Clay had built something unheard of: an entirely in-house cellular manufacturing system, integrated genomics and proteomics, digital pathology, interventional and surgical suites, and AI-powered diagnostics operating as one unified organism. It was not a pitch; instead, they recognized a platform where innovation could happen now, not years from now.
Clay didn’t have to convince them. He simply provided the environment they had long wanted to work in.
How CPI Started and How It Fits Into the Bigger Vision
CPI Stem Cells originated from a real-world need. While running advanced therapies in 2018, Clay’s team noticed that most stem cell providers grew mesenchymal stem cells in normoxic (normal oxygen) conditions, even though scientific literature overwhelmingly supported hypoxic (low oxygen) growth to better mimic natural human physiology. Determined to improve outcomes, they obtained their cellular manufacturing license in 2020 and began producing their own hypoxic MSCs by 2021.
This decision transformed CPI into a global leader in regenerative medicine, treating world champions, NFL athletes, and everyday patients with degenerative, neurological, or musculoskeletal conditions.
But CPI is one component within the larger TAM Center ecosystem. The TAM Center embodies the entire vision: a vertically integrated medical campus that combines science, manufacturing, diagnostics, imaging, interventional radiology, surgery, ICU care, and personalized clinical treatment under one unified system. CPI serves as the stem cell clinical engine inside this broader infrastructure, powered by TAM’s full capabilities.
What Full Integration Means for Patient Outcomes
CPI has become the only stem cell hospital operating within a network that includes 16 PhDs, 42 MDs, an in-house diagnostics lab, a full imaging center, cellular manufacturing facilities, and integrated AI systems. For patients, this unprecedented level of control over data, analysis, and treatment represents far more than operational convenience—it fundamentally reshapes what outcomes are possible. As Clay explains, CPI was never built to check boxes or resemble traditional medical institutions. It was created to address the very real limitations patients experience in today’s fragmented healthcare landscape, where labs are in one location, doctors in another, and critical data is scattered across disconnected systems. Those gaps cost patients time, clarity, and, in too many cases, the chance for the best outcome.
Inside the TAM Center ecosystem, CPI flips that entire model. Everything required to understand and treat complex disease exists in one place, and, more importantly, each element is directly connected to the others. Diagnostics flow immediately into treatment decisions. Genomics becomes a living, interactive tool shared between scientists and physicians rather than a static report. MRI and CT imaging are not interpreted in isolation but reviewed by a multidisciplinary team with direct access to the laboratories and manufacturing suites producing the patient’s therapy.
This level of integration changes the patient experience in ways most will never see but continually benefit from. It is not just a more efficient system—it is a more intelligent one. When scientists and clinicians work side by side, using cutting-edge technologies and shared data, they can design therapeutic strategies that are more adaptive, more individualized, and far more precise. The team doesn’t guess; they learn from each patient in real time and refine protocols as new information emerges.
This close collaboration also accelerates scientific progress. Because the entire team operates under one roof rather than across siloed institutions, discoveries made in the lab can be translated directly to the bedside. It is translational medicine executed in its purest form. With experts trained at many of the world’s leading academic institutions working in alignment toward a singular mission, the CPI and TAM model demonstrates that breaking the mold is not merely disruptive—it is transformative for both science and patient outcomes.
How Ed Clay Plans to Bring This Model to the World
At TAM and CPI, Clay has built an ecosystem that is not only focused on breakthrough innovation but engineered from the ground up to scale. He points out that most medical advancements never reach the patients who need them because the current system is slow, fragmented, and extraordinarily expensive. In traditional biotech, it is common to spend more than $50 million and five to seven years just to move a single therapy into a Phase 1 FDA trial. By contrast, the model developed at TAM is capable of achieving comparable progress in a fraction of the time and cost.
This acceleration is made possible by full vertical integration and by the strategic advantage of operating in Mexico. Through a partnership with the country’s largest CRO, the organization can conduct world-class clinical research with remarkable speed. Clay has also established two biotech platforms—TAM Biosciences, dedicated to cancer therapeutics, and TAM Cell, focused on stem cell and regenerative medicine. These divisions allow discoveries made within the TAM Center to reach patients with unprecedented speed, sometimes within six months of initial identification—an almost unthinkable turnaround in traditional pharmaceutical development.
The speed of this system creates a powerful advantage. It enables the team to quickly determine whether a therapy is effective, how to refine it, and how to structure the most logical and efficient clinical trial. Because manufacturing, diagnostics, genomics, proteomics, digital pathology, and data analysis all occur in-house, the team learns and executes in real time rather than waiting on outside vendors or siloed institutions. In many ways, this represents translational medicine in its purest form: a direct pathway from scientific discovery at the bench to patient application at the bedside.
Although current patients already benefit from this integrated model, Clay emphasized that the broader goal is FDA approval. Democratizing access, he believes, requires making these treatments mainstream, insurance-covered, and widely available through traditional healthcare channels. With its infrastructure already capable of running clinical trials faster and more intelligently than traditional systems, TAM is positioned to compete with (and often outperform) major pharmaceutical companies while maintaining lower costs for patients.
Clay’s approach reimagines what healthcare can be: not only the creation of better therapies, but the construction of a system capable of delivering them rapidly, logically, and at scale.
The Role of Storytelling in Medicine
For Clay and his team, storytelling is not a marketing tool; it is a core pillar of their mission. The work being done at CPI and the TAM Center is extraordinarily advanced, involving complete genomics, cellular manufacturing, and translational research systems that can be difficult for the general public to understand. Clay believes that if they cannot clearly explain what they are doing, why it matters, and who they are as people, then science alone is not enough.
He sees communication as essential to building trust, especially in a field where patients are often overwhelmed by uncertainty. That philosophy led to a years-long documentary project, set for release in 2026, which follows the organization from the inside and gives viewers a transparent look at how the ecosystem was built. Clay also hosts The Ed Clay Show, while his partner Scotty leads the CPI Stem Cell Podcast—both platforms designed to bring patients, families, and the broader public into direct conversation with their doctors, scientists, and collaborators.
In Clay’s view, movements in medicine require stories. People don’t connect with datasets or molecules; they connect with other humans. When someone is facing cancer, chronic illness, or fear about the future, they want to feel they aren’t alone. By opening the doors and sharing their process publicly, Clay and his team aim to demystify their work and show that behind every cutting-edge breakthrough are real people deeply committed to helping patients heal. For him, storytelling isn’t an accessory to the science; it is a critical part of the future of healthcare itself.
Staying Grounded in Science While Pushing Boundaries
Clay’s perspective on this topic is shaped by the evolution of his own work. He acknowledges that years ago, when he was searching for solutions after his mother had exhausted all standard treatments, his efforts might have been viewed as “alternative.” But today, CPI and the TAM Center are no longer associated with that category. Now, they operate one of the most advanced translational medical ecosystems in the world.
Their team includes 16 PhDs and 42 MDs, many of whom are trained at Harvard, Yale, MIT, Cambridge, and Stanford. They conduct full genomic sequencing, proteomics, digital pathology, and in-house cell manufacturing, and they continually gather follow-up data from every patient. Clay emphasizes that what they do is not conjecture or fringe theory—it is hard science supported by rigorous internal systems.
He also points out that many companies marketing genomic testing actually rely on laboratories like his to run their samples. CPI doesn’t outsource that work—they are the lab. They even partner with Roche, one of the world’s largest pharmaceutical companies, on clinical lab work, digital pathology, and sequencing, a collaboration that underscores their legitimacy at the highest scientific level.
In stem cells, the distinction is equally clear. While many clinics purchase off-the-shelf products from external manufacturers, CPI produces its own hypoxic mesenchymal stem cells in-house, with full control over quality, consistency, and safety.
For Clay, staying grounded means staying rooted in outcomes, not hype. He focuses on logic, real-time data, and vertical integration to continually refine the system and reduce costs. His goal is not to chase attention, but to build structures that give patients the best chance at healing. From his perspective, what CPI and TAM are doing is not the medicine of the future; it is the medicine of right now.
What Defines Him Today
While Clay has taken on many roles throughout his life, the title that resonates most deeply with him today is Christian. Every chapter of his journey—from fighting in a cage, to seeking ways to help his mother when conventional medicine failed her, to building CPI and the TAM Center—has been shaped by faith rather than strategy.
He describes his path as a series of moments where he followed where God was leading him, even when it didn’t make sense on paper. His experiences, instincts, and relationships, he believes, weren’t random; they were given to him for a purpose. Whether he is acting as an entrepreneur, a systems architect, a patient advocate, or a healer, the common thread is a commitment to show up fully wherever he feels called.
For Clay, faith is not only a personal identity—it’s the foundation that underpins everything he builds.
About Ed Clay:
Founder and CEO, TAM Global & The TAM Center
Ed Clay is a former MMA fighter turned international healthcare entrepreneur. As the visionary founder of TAM Global, CPI Stem Cells, and the TAM Center in Tijuana, Mexico, he has built a model that unites advanced science, compassionate care, and spiritual healing. His mission is simple, but bold: to revolutionize medicine by putting people, not process, at the center of every cure.
About Michele Hughes:
Michele Hughes is the visionary founder of Ageless and Timeless and the dynamic host of the Ageless and Timeless podcast. As a monthly contributor to Top Doctor Magazine, she offers powerful insights on wellness, longevity, and living fully at every stage of life. With a deep passion for health and vitality, and as a role model of timeless elegance, Michele empowers audiences to embrace their highest potential and live with purpose and grace. Michele’s podcast, Ageless and Timeless, was one of 20 Inaugural Podcasts selected for the Muscle and Fitness Plus platform that began in 2023.
For more information, please reach out to express interest in being a potential guest on the Ageless and Timeless podcast or to be featured in the Top Doctor Magazine Ageless and Timeless column with Michele Hughes. For podcast collaborations or to have Michele Hughes on your show, please contact her at:
Email: themichelehughescompany@gmail.com
Website: www.agelessandtimeless.com
Instagram: @agelessandimeless
LinkedIn: https://www.linkedin.com/in/michele-hughes-83a3b935/
Facebook: https://www.facebook.com/michele.hughes.186
Ageless and Timeless podcast, on YouTube, iTunes, Spotify, and wherever podcasts are available.
